Beloved Portland restaurant to hold steak sale amid temporary closure
PORTLAND, Ore. () — A beloved Portland eatery that was forced to temporarily close earlier this year is giving locals the opportunity to take its high-quality beef home.
'Find yourself missing RingSide's signature steaks?' RingSide Steakhouse on Tuesday. 'Available on our website for preorder now are three different types of our signature Ribeyes. Pickup will be Saturday, June 14th, just in time for Father's Day!'
Some Washington salmon face 'brink' of extinction, report finds
The acclaimed business four 16-ounce prime ribeyes for $158, four 20-ounce prime 35 day dry-aged bone-in ribeyes for $196 and two 34-ounce prime 35 day dry -aged bone-in ribeyes for $162. Each steak will be raw, frozen and individually packaged.
The restaurant's signature steak seasoning is also available for $6.50.
RingSide Steakhouse during the COVID-19 pandemic in April 2020, the first sale in its 75-year-history. The event was expected to last from 10 a.m. to 4 p.m., but it sold out in just two hours. Portland police officers also had to direct drivers as traffic backed up for blocks near the eatery on 2165 W Burnside St.
The upcoming preorder sale follows the steakhouse's temporary shutdown. It was forced to close for repairs and restoration after a on a Saturday afternoon in early April this year. According to a social media post from the owners, there were no injuries and the fire was quickly contained.
The restaurant has yet to reveal when it will reopen.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
40 minutes ago
- Business Insider
Aeluma Inc trading resumes
13:06 EDT Aeluma (ALMU) Inc trading resumes Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yahoo
an hour ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Ramey v. Penn State University: Class action lawsuit payments distributed to students
(WHTM) – Penn State University students who were enrolled in classes at the start of the COVID-19 pandemic are now receiving part of a $17 million class action settlement. On March 16, 2020, the university moved to 'remote instruction' due to the outbreak of COVID-19. Years later, a class action lawsuit was brought on behalf of those who paid tuition and/or fees for the Spring 2020 semester and registered for a class. Close Thanks for signing up! Watch for us in your inbox. Subscribe Now The lawsuit was brought forward with allegations of a breach of contract by the university for not providing the services promised with tuition and fees. The university denied the claims asserted against it and agreed to the $17 million settlement for students who opted in to the lawsuit, known as 'Ramey et al. v. The Pennsylvania State University.' A court granted final approval of the settlement on February 18, 2025, and the deadline to file a claim has since passed. According to the Penn State Tuition Refund Settlement website, payments to eligible class members were sent on June 5, 2025. The website says those who opted to receive payments should have received notification of their award via email and should expect a check in the mail. Payments were automatically sent to the recipients' 'last known permanent postal address on file with Penn State,' according to the settlement website. The deadline to change that address or type of payment has also passed. Of the $17 million in settlement funds, the final judgment awarded attorneys' fees of $5,666,100, deducted litigation expenses worth $17,990.94, and made a $15,000 award for the individuals who initiated the lawsuit. The remaining portion of the money (approximately $11,300,909) was designated as the 'Net Settlement Fund.' Students eligible for payments 'who withdrew for medical reasons from Penn State after March 16, 2020, but before the conclusion of the Spring 2020 semester, and received a refund of tuition,' will receive $50 from the Net Settlement Fund. The remaining funds were then 'distributed equally to all other Settlement Class Members.' Eligible students included those attending branch campuses at the time of the shutdown, according to the settlement. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
